SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000891293-18-000066
Filing Date
2018-05-21
Accepted
2018-05-21 17:16:15
Documents
3
Period of Report
2018-05-21
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a8-kagm2018.htm 8-K 56534
2 EXHIBIT 10.1 a1018-kagm2018.htm EX-10.1 117383
3 EXHIBIT 10.2 a1028-kagm2018.htm EX-10.2 137312
  Complete submission text file 0000891293-18-000066.txt   312623
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 18850526
SIC: 2834 Pharmaceutical Preparations